Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
Rani Therapeutics (Nasdaq: RANI) promoted Alireza Javadi, Ph.D., to Chief Technical Officer effective Jan. 28, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rani Therapeutics (Nasdaq: RANI) promoted Alireza Javadi, Ph.D., to Chief Technical Officer effective Jan. 28, 2026.
In his expanded role, Javadi will continue to lead R&D, manufacturing, and automation and will assume responsibility for quality assurance. Management cites his prior device and life‑sciences operations experience and his tenure at Rani since 2022.
Positive
- Promotes internal leader with R&D and manufacturing oversight since 2022
- CTO role adds formal responsibility for quality assurance and operations
Negative
- None.
Details
News Market Reaction – RANI
On Jan 28, the day this news came out, RANI closed 2.90% below the previous close.
Data tracked by StockTitan Argus for the Jan 28 session.
Historical Context
-
Initiation of Phase 1 RT-114 obesity study in collaboration with ProGen.
-
Participation in Evercore Healthcare Conference with webcast access for investors.
-
Q3 2025 results, Chugai deal up to $1.085B, and financing to extend runway.
-
Preclinical data on oral semaglutide via RaniPill® showing bioequivalence in dogs.
-
New directors appointed and closure of a $60.3M private placement financing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
phase 1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.
“We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase 1 study of RT-114 for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “His technical and operational leadership experience in the medical device and life science industries will be instrumental in scaling our supply chain and manufacturing capabilities as we continue to advance our pipeline.”
Prior to the promotion to Chief Technical Officer, Alireza served as Vice President, Technical Operations, where he was responsible for Rani’s R&D, manufacturing, and automation teams. In this expanded role, he will continue to lead these core functions while also assuming responsibility for quality assurance. Before joining Rani in 2022, he spent five years as Director of Operations at Cretex Medical. Before Cretex, Alireza’s prior roles include Tooling and Engineering Manager at JunoPacific, Senior Process Development Engineer at G&W Electric Co., and Principal Scientist at the Wisconsin Institute for Discovery. He holds a Ph.D. in Materials Science from University of Wisconsin and a Master’s degree in Advanced Engineering Materials from Chalmers University in Sweden.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.